when injecting tirzepatide How to Inject A Simple Guide to Injecting

You might not Check it out

Most copper peptide irritation resolves within 2-4 weeks of stopping the product and using only a gentle cleanser, bland moisturizer, and sunscreen

Kunwar A, Verma P, Bhilwade HN et al (2016) Dihydroxyselenolane (DHS) supplementation improves survival following whole-body irradiation (WBI) by suppressing tissue-specific inflammatory responses

Because tirzepatide slows down gastric emptying and signals your brain to be less hungry, you may also feel fuller and naturally want to consume fewer calories

Last updated on Jul 20, 2026 How to fill out the Publication Consent Form 1

Mechanism of Action Semaglutide: Single GLP-1 Agonist Semaglutide activates only the GLP-1 receptor: GLP-1 Receptor Effects: Stimulates insulin secretion (glucose-dependent) Suppresses glucagon release Slows gastric emptying Reduces appetite via hypothalamic signaling Promotes satiety Tirzepatide: Dual GLP-1/GIP Agonist Tirzepatide activates both GLP-1 and GIP receptors: GLP-1 Receptor Effects: Same as semaglutide (above) GIP Receptor Effects (Additional): Enhanced insulin secretion Direct adipose tissue effects Potential cardioprotective benefits May improve tolerability Complements GLP-1 signaling Why Dual Agonism Matters Semaglutide: GLP-1 Appetite + Glucose Tirzepatide: GLP-1 Appetite + Glucose + GIP Enhanced effects + Better tolerance The dual mechanism may explain tirzepatide's: Greater overall efficacy Potentially better GI tolerability Enhanced metabolic effects Efficacy Comparison Weight Loss Results Semaglutide Clinical Trials STEP 1 (Non-diabetic obesity): 2.4mg dose: 14.9% weight loss Placebo: 2.4% weight loss Duration: 68 weeks STEP 2 (Type 2 diabetes + obesity): 2.4mg dose: 9.6% weight loss Duration: 68 weeks Tirzepatide Clinical Trials SURMOUNT-1 (Non-diabetic obesity): 15mg dose: 20.9% weight loss 10mg dose: 19.5% weight loss Placebo: 3.1% weight loss Duration: 72 weeks SURMOUNT-2 (Type 2 diabetes + obesity): 15mg dose: 15.7% weight loss Duration: 72 weeks Direct Comparison Glycemic Control Side Effects Gastrointestinal Effects GI side effects are the most common with both medications: Key Finding: Tirzepatide shows lower rates of GI side effects despite greater efficacy